The Latest
-
Andrew Harnik via Getty Images
Why TrumpRx is stumbling before it gets off the ground
Concerns about potential kickbacks, costs and conflicts have triggered calls for oversight.
-
Getty Images
Investors crave safer, market-ready biotech bets, widening the early-stage funding gap
In these difficult financial times, venture capital dollars favor later-stage biotechs, forcing drugmakers with earlier-stage candidates to find alternative funding routes.
-
Permission granted by Mirum
Mirum doubles down on diversified rare disease strategy
With the purchase of biotech Bluejay, Mirum stays focused on building a company with a broad pipeline and portfolio devoted to rare diseases.
-
Getty Images
AI regulation lags despite entering higher-risk patient care
While more pharma companies launch DTC platforms, states, not the federal government, are providing guardrails to protect patient privacy and safety.
-
Getty Images
How Big Pharma is navigating a $300 billion patent cliff
Drugmakers like J&J, Merck and AbbVie are making gains by not relying on one single strategy to shore up losses.
-
Getty Images
Year in PreviewPharma’s outlook in 2026: Smoother sailing ahead?
After a turbulent year, the industry has a clearer picture of its new landscape and how to navigate the challenges and opportunities ahead.
-
Scott Olson via Getty Images
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
The promising anti-inflammation target could be the next big thing in cardiovascular and other diseases.
-
Andrew Harnik/ via Getty Images
Q&APoliticization runs deeper than ever at FDA, risking long-term impacts
Wide-ranging shifts at the FDA have set the stage for decisions that drag the agency through the political mud, according to an economist and public policy expert.
-
Carsten Koall via Getty Images
Has Novavax cracked the code for survival in the vaccine arena?
The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.
-
Permission granted by Medera
A potential gene therapy for heart failure is an approach decades in the making
Medera’s mid-stage heart failure gene therapy leverages a “master switch” that could widen the aperture of genetic medicine.
-
Getty Images
Biopharma layoffs surged last year, but 2026 is a chance to turn the page
Companies are adjusting to turbulence in the U.S. market, and more traditional job loss factors will likely be at play in the coming year.
-
Getty Images
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines
Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.
-
Getty Images
Top pharma industry conferences in 2026
Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.
Updated Jan. 26, 2026 -
Getty Images
US drug pricing policies are ‘red lights’ for investors, and China beckons
Pricing policies like most-favored nation and the Inflation Reduction Act, as well as a destabilized FDA, are pushing investors to look outside the U.S.
-
Getty Images
Cancer R&D is thriving. Here are the areas to watch in 2026.
ADCs, radioligand therapies and multispecifics are leading the way in cancer innovation.
-
Getty Images
Lilly, Takeda targeted by legal strategy usually reserved for the mob
A case targeting alleged fraud around the safety risk of a blockbuster diabetes drug is leveraging the RICO pathway and could have a ripple effect in pharma.
-
Getty Images
Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged
Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.
-
Getty Images
The clinical candidates pharma execs are tracking
Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.
-
Samuel Corum via Getty Images
Trump unveils healthcare affordability plan
The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench Trump’s drug pricing deals.
-
Getty Images
It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?
The “trauma” faced by pharma execs in 2025 kept M&A at a low simmer, experts say, but as predictability returns, dealmaking could be turned up.
-
Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Market and policy forces shaping the industry
How pharma leaders believe the regulatory and investment market landscape will change in 2026.
-
Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: What’s next for AI and drug R&D
Industry execs foresee drug innovation and AI breakthroughs in 2026.
-
Zmaj88
Year in Preview5 FDA drug approvals to watch in 2026
Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this year.
-
Getty Images
Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
The GLP-1 giants are the first to try out this new model, but more companies may follow.
-
APCortizasJr via Getty Images
3 positive trends for Massachusetts’ biopharma sector
Despite a rocky landscape for the biotech industry nationally, Massachusetts has shown innovation growth and stronger funding than expected, which could bode well for the future.
